Helus Pharma finishes enrollment in Phase 3 MDD study, sets Q1 2027 GAD trial start
The company reported fiscal second-quarter results with its pivotal HLP003 depression study fully enrolled and topline data still expected in the fourth quarter of 2026.
Helus Pharma Inc. reported financial results for the fiscal quarter ended September 30, 2026 on November 16, 2026, alongside several pipeline updates. During the quarter, the company finished enrolling its Phase 3 APPROACH study, which is testing HLP003 as an add-on treatment for adults with moderate to severe major depressive disorder who had not responded adequately to a stable antidepressant regimen, with 223 patients enrolled.1 The company said the topline data from APPROACH remains on track for the fourth quarter of 2026.1
Two other studies in the same program are moving forward. Enrollment is ongoing in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program,1 and patients are rolling over into the EXTEND long-term extension study, which will look at long-term safety, how durable the treatment effect is, and whether redosing has a role.1
For a separate program, Helus Pharma finalized the design of a Phase 2 monotherapy study of HLP004 in generalized anxiety disorder, a randomized, double-blind, placebo-controlled trial testing two 30 mg doses given three weeks apart against placebo in about 144 adults with GAD and a baseline Hamilton Anxiety Rating Scale score of 20 or higher, with the primary endpoint measured at Week 6 and a key secondary endpoint at Week 12.1 The company said it intends to start this Phase 2 HLP004 study in the first quarter of 2027.1 Separately, the company's HLP005 program is expected to yield a development candidate in the second half of 2027.1
On personnel, Helus Pharma named Michael Halstead as Chief Executive Officer and added Dr. Suresh Durgam, former Chief Medical Officer of Intra-Cellular Therapies, Inc., to its board, along with Mark Lawson as independent Board Chair.
Financially, the company held $171.1 million in cash as of September 30, 2026.1 Net loss for the quarter was $103.1 million, compared with $33.7 million a year earlier.1 The company attributed higher costs to continued advancement of the APPROACH, EMBRACE, and EXTEND HLP003 Phase 3 trials.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.